Two Drugs, One Stunning Myeloma Result

By pairing a BCMA-targeted T-cell engager with an anti-CD38 antibody, researchers achieved strikingly deep remissions and sharply reduced relapse risk in patients with relapsed myeloma. The results suggest this dual immune-directed strategy could challenge current treatment sequencing, including when to deploy engineered T-cell therapies.